ResearchPod Summary
Gestational hypertension (GH) remains a significant driver of maternal morbidity and mortality, frequently leading to long-term cardiovascular risks. While endothelial dysfunction and reduced nitric oxide (NO) bioavailability are known components of hypertensive disorders in pregnancy, the precise link between NO levels and other known cardiovascular (CV) risk factors—such as sympathovagal imbalance, impaired baroreflex sensitivity (BRS), and systemic inflammation—has remained poorly characterized in high-risk pregnancies.
This study followed 96 pregnant women who presented with clinical risk factors for developing GH (e.g., family history, advanced maternal age, high BMI). Researchers measured a wide array of physiological and biochemical markers at both the 16th week and 36th week of gestation. Specifically, they assessed blood pressure variability (BPV), heart rate variability (HRV), BRS, inflammatory markers (hsCRP, IL-6), oxidative stress (MDA), and insulin resistance (HOMA-IR), alongside plasma NO concentrations. Statistical analyses, including correlation and multiple regression, were used to identify which factors were independently linked to the observed decline in NO levels by the third trimester.
As pregnancy progressed to the 36th week, the subjects showed a clear, significant decline in NO levels, alongside reduced parasympathetic tone, increased sympathetic activity (sympathovagal imbalance), and impaired BRS. Regression analysis revealed that BRS was the most significant independent predictor of NO levels. Furthermore, the findings suggest that the inflammatory marker interleukin-6 is tied to this decline in NO, potentially reflecting a pro-inflammatory state that precedes overt hypertension. While oxidative stress and insulin resistance also worsened, they did not show an independent association with NO levels in the final model. These results reinforce the notion that autonomic dysregulation, as marked by reduced BRS and vagal withdrawal, is a key physiological feature linked to reduced NO bioavailability in high-risk pregnancies.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.